Welcome To Alimera Sciences

We are a biopharmaceutical company that researches, develops and commercializes prescription ophthalmic pharmaceuticals. Our efforts are currently focused on diseases affecting the lining in the back of the eye, or retina, because these diseases are either not treated pharmacologically or are in need of improved treatments. As the world’s population continues to age, more and more people will be afflicted by these diseases. We created Alimera in June 2003, with the vision to bring innovative products to treat eye disease, specifically diseases that affect the retina, and to be guided by our experience of knowing the right things to do and our desire to “do the right thing” in our daily approach to the business. We invite you to learn more about us through our website.

Iluvien™ (fluocinolone acetonide) intravitreal insert

Retinal disease treatment - IluvienIluvien, an innovative new product, is currently undergoing global clinical trials for the treatment of (DME). The FAME (Fluocinolone Acetonide in Diabetic Macular Edema) Study is tracking results of an innovative new intravitreal insert (smaller than a grain of rice as shown in the picture above) that is placed in the eye by a retinal specialist with a proprietary 25 gauge inserter. Iluvien then slowly releases a very low dose of the corticosteroid fluocinolone acetonide directly into the vitreous, the thick transparent substance that fills the center of the eye, for up to three years.
Learn more about Iluvien...
 
July 03, 2009

Alimera Sciences Announces Presentation Of Data From The 12-Month Interim Readout Of The Human PK ILUVIEN™ Study At ARVO 2009 Annual Meeting

Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced that positive interim 12-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien™ (fluocinolone acetonide (FA) intravitreal insert) will be presented today at 2:00 p.m. at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Ft. Lauderdale, FL.
 Read More...

Alimera Sciences’ Iluvien™ Phase 3 Studies For DME Pass Final DSMB Review Prior To October Readout

Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported that an independent Data Safety Monitoring Board (DSMB) has recommended the continuation of two pivotal Phase 3 clinical trials for the use of Iluvien™ in the treatment of diabetic macular edema (DME) under the current protocol, without change. The Board completed its final review of the currently available safety and efficacy data prior to the readout in October 2009. A DSMB provides an independent evaluation of all trial data to identify potential safety issues that might warrant modification or early termination of ongoing clinical studies.
 Read More...